- Home
- TYRA vs MGTX Comparison
TYRA vs MGTX Comparison
Compare TYRA & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- MGTX
- Stock Information
- Founded
- TYRA 2018
- MGTX 2015
- Country
- TYRA United States
- MGTX United States
- Employees
- TYRA N/A
- MGTX N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TYRA Health Care
- MGTX Health Care
- Exchange
- TYRA Nasdaq
- MGTX Nasdaq
- Market Cap
- TYRA 576.6M
- MGTX 515.7M
- IPO Year
- TYRA 2021
- MGTX N/A
- Fundamental
- Price
- TYRA $9.52
- MGTX $5.43
- Analyst Decision
- TYRA Strong Buy
- MGTX Strong Buy
- Analyst Count
- TYRA 7
- MGTX 2
- Target Price
- TYRA $30.86
- MGTX $24.00
- AVG Volume (30 Days)
- TYRA 298.0K
- MGTX 658.4K
- Earning Date
- TYRA 05-08-2025
- MGTX 05-13-2025
- Dividend Yield
- TYRA N/A
- MGTX N/A
- EPS Growth
- TYRA N/A
- MGTX N/A
- EPS
- TYRA N/A
- MGTX N/A
- Revenue
- TYRA N/A
- MGTX $34,508,000.00
- Revenue This Year
- TYRA N/A
- MGTX $382.62
- Revenue Next Year
- TYRA N/A
- MGTX $66.88
- P/E Ratio
- TYRA N/A
- MGTX N/A
- Revenue Growth
- TYRA N/A
- MGTX 203.23
- 52 Week Low
- TYRA $6.42
- MGTX $3.85
- 52 Week High
- TYRA $29.60
- MGTX $8.75
- Technical
- Relative Strength Index (RSI)
- TYRA 45.60
- MGTX 45.94
- Support Level
- TYRA $8.88
- MGTX $5.02
- Resistance Level
- TYRA $9.68
- MGTX $5.38
- Average True Range (ATR)
- TYRA 0.64
- MGTX 0.36
- MACD
- TYRA -0.08
- MGTX 0.03
- Stochastic Oscillator
- TYRA 26.98
- MGTX 60.57
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.